

S6 Table. Univariate analysis in the oligoprogression group (n=122)

Variable	sPFS		OS	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Sex (female vs. male)	0.73 (0.49-1.11)	0.139	0.73 (0.47-1.12)	0.151
Age (\geq 60 yr vs. < 60 yr)	0.76 (0.50-1.16)	0.761	1.13 (0.72-1.79)	0.596
EGFR (positive vs. negative)	0.93 (0.61-1.40)	0.711	0.73 (0.47-1.13)	0.155
ALK (positive vs. negative)	0.79 (0.32-1.94)	0.601	0.81 (0.30-2.23)	0.688
ROS1 (positive vs. negative)	1.48 (0.64-3.40)	0.358	1.04 (0.42-2.58)	0.929
PD-L1 (positive vs. negative)	0.97 (0.64-1.48)	0.898	1.66 (1.08-2.57)	0.022
Number of metastatic lesions (per 1 lesion)	1.03 (0.76-1.40)	0.854	0.92 (0.66-1.29)	0.625
Systemic therapy (TKI vs. no TKI)	0.88 (0.58-1.32)	0.534	0.70 (0.46-1.08)	0.111
RT site (bone vs. others)	0.88 (0.59-1.33)	0.555	0.83 (0.54-1.29)	0.403
EQD2 (\geq 43.9 Gy vs. < 43.9 Gy)	0.76 (0.50-1.14)	0.186	0.93 (0.60-1.44)	0.752

ALK, anaplastic lymphoma receptor tyrosine kinase; CI, confidence interval; EGFR, epidermal growth factor receptor; EQD2, equivalent doses in 2 Gy fractions; HR, hazard ratio; OS, overall survival; PD-L1, programmed death-ligand 1; ROS1, c-ros oncogene 1; RT, radiotherapy; sPFS, subsequent progression-free survival; TKI, tyrosine kinase inhibitor.